Depletion of CD25+ regulatory cells results in suppression of melanomagrowth and induction of autoreactivity in mice

Cancer Immunity

Volumn 5, Issue , 2002, Pages 1-12

  Jones, Emma ^a   Dahm Vicker, Michaela ^a   Simon, Anna Katharina ^b   Green, Angharad ^a   Powrie, Fiona ^c   Cerundolo, Vincenzo ^a   Gallimore, Awen ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

CD25; Mice; T cell subsets; Tumor antigens; Tumor immunity

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; MONOPHENOL MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; CANCER INHIBITION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; LYMPHOCYTE COUNT; MELANOMA; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR REJECTION; VACCINIA VIRUS; VIRUS RECOMBINANT;

EID: 3242736641     PISSN: 14249634     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Houghton AN, Gold JS, Blachere NE. Immunity against cancer: lessons learned from melanoma. Curr Opin Immunol 2001; 13: 134-40. (PMID: 11228404)
2. Shevach EM. Regulatory T cells in autoimmunity*. Annu Rev Immunol 2000; 18: 423-49. (PMID: 10837065)
3. Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 2000; 164: 183-90. (PMID: 10605010)
4. Suri-Payer E, Amar AZ, Thornton AM, Shevach EM. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998; 160: 1212-8. (PMID: 9570536)
5. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J Exp Med 2000; 192: 295-302. (PMID: 10899916)
6. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12: 431-40. (PMID: 10795741)
7. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999; 163: 5211-8. (PMID: 10553041)
8. Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 1998; 280: 243-8. (PMID: 9535647)
9. Lowenthal JW, Corthesy P, Tougne C, Lees R, MacDonald HR, Nabholz M. High and low affinity IL 2 receptors: analysis by IL 2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC61. J Immunol 1985; 135: 3988-94. (PMID: 3934270)
10. Jankovic DL, Rebollo A, Kumar A, Gibert M, Theze J. IL-2-dependent proliferation of murine T cells requires expression of both the p55 and p70 subunits of the IL-2 receptor. J Immunol 1990; 145: 4136-44. (PMID: 2258612)
11. Fidler IJ. Selection of successive tumour lines for metastasis. Nat New Biol 1973; 242: 148-49. (PMID: 4512654)
12. Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J Exp Med 2000; 192: 1637-44. (PMID: 11104805)
13. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988; 240: 1169-76. (PMID: 3131876)
14. Qin Z, Blankenstein T. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000; 12: 677-86. (PMID: 10894167)
15. Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, Schreiber H. CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci U S A 1999; 96: 8633-8. (PMID: 10411927)
16. Segal BM, Glass DD, Shevach EM. Cutting Edge: IL-10-producing CD4+ T cells mediate tumor rejection. J Immunol 2002; 168: 1-4. (PMID: 11751938)
17. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief, CJ. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194: 823-32. (PMID: 11560997)
18. Cobbold SP, Jayasuriya A, Nash A, Prospero TD, Waldmann H. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 1984; 312: 548-51. (PMID: 6150440)
19. Qin S, Cobbold S, Tighe H, Benjamin R, Waldmann H. CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. Eur J Immunol 1987; 17: 1159-65. (PMID: 2441998)
20. Lehmann-Grube F, Assmann U, Loliger C, Moskophidis D, Lohler J. Mechanism of recovery from acute virus infection. I. Role of T lymphocytes in the clearance of lymphocytic choriomeningitis virus from spleens of mice. J Immunol 1985; 134: 608-15. (PMID: 3871115)
21. Mackett M, Yilma T, Rose JK, Moss B. Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Science 1985; 227: 433-5. (PMID: 2981435)
22. Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz, TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998; 188: 277-86. (PMID: 9670040)
23. Townsend A, Bastin J, Gould K, Brownlee G, Andrew M, Coupar B, Boyle D, Chan S, Smith G. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J Exp Med 1988; 168: 1211-24. (PMID: 2459295)